Trilaciclib Use and Chemotherapy-Induced Myelosuppression Among Patients with ES- SCLC in US Community Oncology Settings

Abstract

BACKGROUNDChemotherapy-induced myelosuppression, which leads to reduced production of multiple cell lineages (white blood cells, red blood cells [RBCs], and/or platelets), is a major dose-limiting toxicity of chemotherapy. A previous study reported 56.6% of chemotherapy-treated patients with extensive-stage small cell lung cancer (ES-SCLC) in The US Oncology Network ('Network') had grade ≥3 myelosuppression events in ≥1 lineage and 33.0% in ≥2 lineages after chemotherapy initiation. 1 This study evaluated real-world outcomes in patients with ES-SCLC treated with trilaciclib in the community oncology setting.

Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy

“…The literature search yielded one published journal article [ 14 ] and four conference presentations [ 34 – 37 ] as of the search date. Communications with the authors of the identified studies produced one unpublished manuscript as of the search date but published at the time of manuscript development [ 38 ] and two accepted conference presentations [ 39 , 40 ].…”

“…Communications with the authors of the identified studies produced one unpublished manuscript as of the search date but published at the time of manuscript development [ 38 ] and two accepted conference presentations [ 39 , 40 ]. Therefore, a total of eight manuscripts and conference presentations were identified [ 14 , 34 – 40 ] (Fig. 1 ), of which, six reported five unique original studies [ 14 , 34 – 38 ] and two presented results from the additional analyses of three original studies [ 39 , 40 ].…”

“…Therefore, a total of eight manuscripts and conference presentations were identified [ 14 , 34 – 40 ] (Fig. 1 ), of which, six reported five unique original studies [ 14 , 34 – 38 ] and two presented results from the additional analyses of three original studies [ 39 , 40 ]. Of the five unique studies, one included a trilaciclib cohort and a historical non-trilaciclib cohort [ 37 ]; two focused on trilaciclib only [ 34 , 35 ]; and the rest included the corresponding historical non-trilaciclib cohorts for the trilaciclib-only studies [ 14 , 36 , 38 ].…”

“…1 ), of which, six reported five unique original studies [ 14 , 34 – 38 ] and two presented results from the additional analyses of three original studies [ 39 , 40 ]. Of the five unique studies, one included a trilaciclib cohort and a historical non-trilaciclib cohort [ 37 ]; two focused on trilaciclib only [ 34 , 35 ]; and the rest included the corresponding historical non-trilaciclib cohorts for the trilaciclib-only studies [ 14 , 36 , 38 ]. In total, the five studies reported the results for eight distinctive cohorts of trilaciclib and historical non-trilaciclib users.…”

“…All five studies [ 14 , 34 – 38 ] were retrospective cohort studies based on four existing oncology databases in the USA: the US Oncology Network’s electronic health record (EHR) system, iKnowMed (iKM), the Florida Cancer Specialists and Research Institute (FCS) structured electronic medical record (EMR) database, and the Integra Connect Precision De-Identified Structured & Unstructured EMR and Claims database (Table 1 ). The US Oncology iKM database is implemented across the US Oncology Network (“network”) and non-network community oncology practices (“non-network”) made up of approximately 80 clinics that have adopted iKM EHRs.…”